Specialty Generics Market Size, Share, and Trends 2024 to 2033

Chapter 1. Introduction

1.1. Research Objective

1.2. Scope of the Study

1.3. Definition

Chapter 2. Research Methodology

2.1. Research Approach

2.2. Data Sources

2.3. Assumptions & Limitations

Chapter 3. Executive Summary

3.1. Market Snapshot

Chapter 4. Market Variables and Scope 

4.1. Introduction

4.2. Market Classification and Scope

4.3. Industry Value Chain Analysis

4.3.1. Raw Material Procurement Analysis 

4.3.2. Sales and Distribution Channel Analysis

4.3.3. Downstream Buyer Analysis

Chapter 5. COVID 19 Impact on Specialty Generics Market 

5.1. COVID-19 Landscape: Specialty Generics Industry Impact

5.2. COVID 19 - Impact Assessment for the Industry

5.3. COVID 19 Impact: Global Major Government Policy

5.4. Market Trends and Opportunities in the COVID-19 Landscape

Chapter 6. Market Dynamics Analysis and Trends

6.1. Market Dynamics

6.1.1. Market Drivers

6.1.2. Market Restraints

6.1.3. Market Opportunities

6.2. Porter’s Five Forces Analysis

6.2.1. Bargaining power of suppliers

6.2.2. Bargaining power of buyers

6.2.3. Threat of substitute

6.2.4. Threat of new entrants

6.2.5. Degree of competition

Chapter 7. Competitive Landscape

7.1.1. Company Market Share/Positioning Analysis

7.1.2. Key Strategies Adopted by Players

7.1.3. Vendor Landscape

7.1.3.1. List of Suppliers

7.1.3.2. List of Buyers

Chapter 8. Global Specialty Generics Market, By Type

8.1. Specialty Generics Market Revenue and Volume, by Type, 2024-2033

8.1.1 Injectables

8.1.1.1. Market Revenue and Volume Forecast (2021-2033)

8.1.2. Oral drugs

8.1.2.1. Market Revenue and Volume Forecast (2021-2033)

8.1.3. Others

8.1.3.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 9. Global Specialty Generics Market, By Application

9.1. Specialty Generics Market Revenue and Volume, by Application, 2024-2033

9.1.1. Oncology

9.1.1.1. Market Revenue and Volume Forecast (2021-2033)

9.1.2. Inflammatory Conditions

9.1.2.1. Market Revenue and Volume Forecast (2021-2033)

9.1.3. Multiple Sclerosis

9.1.3.1. Market Revenue and Volume Forecast (2021-2033)

9.1.4. Hepatitis C

9.1.4.1. Market Revenue and Volume Forecast (2021-2033)

9.1.5. Others

9.1.5.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 10. Global Specialty Generics Market, By End-Use 

10.1. Specialty Generics Market Revenue and Volume, by End-Use, 2024-2033

10.1.1. Specialty Pharmacy

10.1.1.1. Market Revenue and Volume Forecast (2021-2033)

10.1.2. Retail Pharmacy

10.1.2.1. Market Revenue and Volume Forecast (2021-2033)

10.1.3. Hospital Pharmacy

10.1.3.1. Market Revenue and Volume Forecast (2021-2033)

Chapter 11. Global Specialty Generics Market, Regional Estimates and Trend Forecast

11.1. North America

11.1.1. Market Revenue and Volume Forecast, by Type (2021-2033)

11.1.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.1.3. Market Revenue and Volume Forecast, by End-Use (2021-2033)

11.1.4. U.S.

11.1.4.1. Market Revenue and Volume Forecast, by Type (2021-2033)

11.1.4.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.1.4.3. Market Revenue and Volume Forecast, by End-Use (2021-2033)

11.1.5. Rest of North America

11.1.5.1. Market Revenue and Volume Forecast, by Type (2021-2033)

11.1.5.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.1.5.3. Market Revenue and Volume Forecast, by End-Use (2021-2033)

11.2. Europe

11.2.1. Market Revenue and Volume Forecast, by Type (2021-2033)

11.2.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.2.3. Market Revenue and Volume Forecast, by End-Use (2021-2033)

11.2.4. UK

11.2.4.1. Market Revenue and Volume Forecast, by Type (2021-2033)

11.2.4.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.2.4.3. Market Revenue and Volume Forecast, by End-Use (2021-2033)

11.2.5. Germany

11.2.5.1. Market Revenue and Volume Forecast, by Type (2021-2033)

11.2.5.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.2.5.3. Market Revenue and Volume Forecast, by End-Use (2021-2033)

11.2.6. France

11.2.6.1. Market Revenue and Volume Forecast, by Type (2021-2033)

11.2.6.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.2.6.3. Market Revenue and Volume Forecast, by End-Use (2021-2033)

11.2.7. Rest of Europe

11.2.7.1. Market Revenue and Volume Forecast, by Type (2021-2033)

11.2.7.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.2.7.3. Market Revenue and Volume Forecast, by End-Use (2021-2033)

11.3. APAC

11.3.1. Market Revenue and Volume Forecast, by Type (2021-2033)

11.3.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.3.3. Market Revenue and Volume Forecast, by End-Use (2021-2033)

11.3.4. India

11.3.4.1. Market Revenue and Volume Forecast, by Type (2021-2033)

11.3.4.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.3.4.3. Market Revenue and Volume Forecast, by End-Use (2021-2033)

11.3.5. China

11.3.5.1. Market Revenue and Volume Forecast, by Type (2021-2033)

11.3.5.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.3.5.3. Market Revenue and Volume Forecast, by End-Use (2021-2033)

11.3.6. Japan

11.3.6.1. Market Revenue and Volume Forecast, by Type (2021-2033)

11.3.6.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.3.6.3. Market Revenue and Volume Forecast, by End-Use (2021-2033)

11.3.7. Rest of APAC

11.3.7.1. Market Revenue and Volume Forecast, by Type (2021-2033)

11.3.7.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.3.7.3. Market Revenue and Volume Forecast, by End-Use (2021-2033)

11.4. MEA

11.4.1. Market Revenue and Volume Forecast, by Type (2021-2033)

11.4.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.4.3. Market Revenue and Volume Forecast, by End-Use (2021-2033)

11.4.4. GCC

11.4.4.1. Market Revenue and Volume Forecast, by Type (2021-2033)

11.4.4.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.4.4.3. Market Revenue and Volume Forecast, by End-Use (2021-2033)

11.4.5. North Africa

11.4.5.1. Market Revenue and Volume Forecast, by Type (2021-2033)

11.4.5.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.4.5.3. Market Revenue and Volume Forecast, by End-Use (2021-2033)

11.4.6. South Africa

11.4.6.1. Market Revenue and Volume Forecast, by Type (2021-2033)

11.4.6.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.4.6.3. Market Revenue and Volume Forecast, by End-Use (2021-2033)

11.4.7. Rest of MEA

11.4.7.1. Market Revenue and Volume Forecast, by Type (2021-2033)

11.4.7.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.4.7.3. Market Revenue and Volume Forecast, by End-Use (2021-2033)

11.5. Latin America

11.5.1. Market Revenue and Volume Forecast, by Type (2021-2033)

11.5.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.5.3. Market Revenue and Volume Forecast, by End-Use (2021-2033)

11.5.4. Brazil

11.5.4.1. Market Revenue and Volume Forecast, by Type (2021-2033)

11.5.4.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.5.4.3. Market Revenue and Volume Forecast, by End-Use (2021-2033)

11.5.5. Rest of LATAM

11.5.5.1. Market Revenue and Volume Forecast, by Type (2021-2033)

11.5.5.2. Market Revenue and Volume Forecast, by Application (2021-2033)

11.5.5.3. Market Revenue and Volume Forecast, by End-Use (2021-2033)

Chapter 12. Company Profiles

12.1. Teva Pharmaceuticals Industries Ltd.

12.1.1. Company Overview

12.1.2. Product Offerings

12.1.3. Financial Performance

12.1.4. Recent Initiatives

12.2. Viatris Inc.

12.2.1. Company Overview

12.2.2. Product Offerings

12.2.3. Financial Performance

12.2.4. Recent Initiatives

12.3. Novartis AG (Sandoz International GmbH)

12.3.1. Company Overview

12.3.2. Product Offerings

12.3.3. Financial Performance

12.3.4. Recent Initiatives

12.4. Hikma Pharmaceuticals PLC

12.4.1. Company Overview

12.4.2. Product Offerings

12.4.3. Financial Performance

12.4.4. Recent Initiatives

12.5. Mallinckrodt

12.5.1. Company Overview

12.5.2. Product Offerings

12.5.3. Financial Performance

12.5.4. Recent Initiatives

12.6. Bausch Health Companies Inc. (Valeant Pharmaceuticals International, Inc.)

12.6.1. Company Overview

12.6.2. Product Offerings

12.6.3. Financial Performance

12.6.4. Recent Initiatives

12.7. Dr. Reddy’s Laboratories Ltd.

12.7.1. Company Overview

12.7.2. Product Offerings

12.7.3. Financial Performance

12.7.4. Recent Initiatives

12.8. Endo Pharmaceuticals Inc.

12.8.1. Company Overview

12.8.2. Product Offerings

12.8.3. Financial Performance

12.8.4. Recent Initiatives

12.9. Apotex Corp.

12.9.1. Company Overview

12.9.2. Product Offerings

12.9.3. Financial Performance

12.9.4. Recent Initiatives

12.10. Sun Pharmaceutical Industries Ltd.

12.10.1. Company Overview

12.10.2. Product Offerings

12.10.3. Financial Performance

12.10.4. Recent Initiatives

Chapter 13. Research Methodology

13.1. Primary Research

13.2. Secondary Research

13.3. Assumptions

Chapter 14. Appendix

14.1. About Us

14.2. Glossary of Terms